ReviewCurrent opinion in HIV and AIDS2016
Tenofovir and bone health.
Review in Current opinion in HIV and AIDS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05313477 (The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate), which is not on this map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Hard facts and misfits: essential ingredients of public health nutrition research.The Proceedings of the Nutrition Society · 2021Pooled it
- Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic Review.Journal of managed care & specialty pharmacy · 2020Pooled it
- Bone Mineral Content, Growth, and Renal Health of Infants With Perinatal Exposure to Maternal Dolutegravir Versus Efavirenz and Tenofovir Disoproxil Fumarate Versus Tenofovir Alafenamide: The Randomized IMPAACT 2010 (VESTED) Trial.Journal of acquired immune deficiency syndromes (1999) · 2025Trial
- Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.The Journal of antimicrobial chemotherapy · 2022Trial
- Trial
- Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.Journal of the International AIDS Society · 2020Trial
- Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.Current HIV research · 2020Trial
- Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.Journal of acquired immune deficiency syndromes (1999) · 2019Trial
- Changes in Bone Mineral Density, Body Composition, Vitamin D Status, and Mineral Metabolism in Urban HIV-Positive South African Women Over 12 Months.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Trial
- Trial
- Sex-specific bone architectural deficits among older adults living with HIV: a cross-sectional study from Zimbabwe.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Article
- Bone health across the lifespan in African populations affected by HIV.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Article
- Longitudinal comparison of bone, growth, and biochemical markers in breastfed HIV-exposed uninfected and HIV-unexposed Ugandan children.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Article
- Clinical insights into the association between chronic liver disease and osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Infected Adults with TDF-Related Renal or Bone Toxicity.Infectious diseases and therapy · 2026Article
- Premature Skeletal Aging and Immunological Recovery in Romanian PLWH: A Cross-Sectional Analysis of Gender-Specific and Metabolic Risk Factors.International journal of molecular sciences · 2026Article
- Analysis of potential barriers for PrEP non-users among PrEP-eligible MSM in Germany.BMC public health · 2026Article
- Bone Health in People Living with HIV: From Pathophysiology to Practical Management.Infection & chemotherapy · 2026Review
- Vitamin D Status in People Living with HIV: Assessment of 25(OH)D Levels and Associated Factors-A Cross-Sectional Study.Metabolites · 2026Article
- Bilateral Pathological Femoral Fractures Secondary to Long-Term Tenofovir Disoproxil Fumarate-Induced Osteomalacia in a Woman Living with HIV: A Case Report.International medical case reports journal · 2026Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewWith continued improvements to the antiviral efficacy and tolerability of antiretroviral therapy, long-term safety of antiretroviral therapy has become paramount. Low bone mineral density and fragility fractures are more common in HIV-infected individuals than in the general population. The aims of this review are to describe potential mechanisms underlying the adverse effects of tenofovir on bone, clinical studies of tenofovir disoproxil fumarate (TDF) and bone, and more recent bone data on tenofovir alafenamide. RECENT FINDING: Several studies have demonstrated an approximately 1-3% greater bone mineral density loss with TDF compared with other agents. Recent studies with tenofovir alafenamide have shown improved bone (and renal) safety with similar virologic efficacy when compared to TDF. SUMMARY: Given these findings, TDF-containing regimens may be gradually replaced with non-TDF containing regimens for the treatment of HIV infection, especially in those at higher risk for fragility fracture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.